A study investigated if observing positive drug effects on pain and mobility in another patient increases pain reduction and functional capacity in other patients.
Data for this study were sourced from the National Health Interview Survey (NHIS) which was conducted in 2019.
Researchers evaluated the therapeutic potential of topical cannabidiol (CBD) for treating pain associated with thumb basal joint arthritis.
Pentoxifylline decreased pain in the setting of lower back pain with radiculopathy due to lumbar disc herniation.
Patients with hand osteoarthritis or psoriatic arthritis with 100-point visual analogue scale pain scores of ≥30 mm were randomized to receive 10 mg daily oral CBD increased to twice daily after 2 weeks or placebo for 12 weeks.
Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.
Oral synthetic cannabinoid products with high THC-to-CBD ratios are associated with moderate short-term improvement in chronic pain.
An individualized approach is needed for the successful transition from pediatric to adult chronic pain care.
From 2016 to 2019, there was a decline in the percentage of patients receiving concurrent opioid and benzodiazepine prescriptions.
The approval was based upon a bioavailability study in healthy adults comparing baclofen oral tablets to Lyvispah.
